FIG. 2.
Effects of α-defensin-1 on HIV-1 entry. Activated CD4+ T lymphocytes were treated with 5 μg of α-defensin-1/ml at the same time as (A) or 2 h after (B) infection by HIV-1HxB2 Env-pseudotyped virus. Cells were also treated with CAF (50%K) and 1 μM CXCR4 entry inhibitor AMD3100 as controls. Luciferase activity (in RLU) was measured at 48 h p.i. The results (means ± standard deviations) from triplicate determinations in a single experiment are presented as histograms. Similar results were obtained in an independent experiment.